% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, AŞ Message Board

  • weightbayou weightbayou Apr 27, 2013 11:58 AM Flag

    Astex new Alzheimers drug is AZD3293—Beta-secretase inhibitor

    Bucket, you will be glad to know that AZD3293 is mentioned on Astex's website.

    AZD3293—Beta-secretase inhibitor (Alzheimer’s)Beta-secretase, also called BACE1 (beta-site of amyloid precursor protein cleaving enzyme) or memapsin-2, is an aspartic-acid protease important in the formation of myelin sheaths in peripheral nerve cells and in the pathogenesis of Alzheimer’s disease. Inhibitors to block the action of this enzyme could prevent the build up of beta-amyloid, which may help slow the progression of, or stop, the disease.

    A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients
    This study is currently recruiting participants.
    Verified March 2013 by AstraZeneca
    Information provided by (Responsible Party): Identifier:
    First received: February 18, 2013
    Last updated: March 22, 2013
    Last verified: March 2013
    History of Changes

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It looks like azd3292 replaces azd3839. Interesting that they spent a year with the first drug with 72 patients and now have gone to the second drug. Do you view this as a good sign of things to come? I think it's wreckless to tell investors that this stock is headed to $15. There's another redflag showing up on your lead drug. SGI-110 just recently waterdown the primary and secondary outcomes in their liver trial. I can show you where these are the things to watch out for in a biotech. Glad that all the money astra zeneca paid the former owners, there's still a small hope that the second drug will get to phase 2. It's one thing to post as you do when the stocks at $2, it's concerning to continue to pump things that are 4 years away.

      Sentiment: Sell

      • 1 Reply to bucketlist88
      • Bucket, you need to look at the big pitcher. What other biotech has as many compounds under development, 130+ million in bank, revenue stream (70+ million), partnerships plus two compounds under their development with billion dollar potential and making progress all for a $6 to $7 share price? Current analysts at RBC have a $9 price target. You are the only one who sold and wants to buy back in at $4.5. Stop spewing your nonsense.

        Sentiment: Strong Buy